Search Results

You are looking at 91 - 100 of 286 items for :

  • "risk assessment" x
  • Refine by Access: All x
Clear All
Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Simon Kim, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Kelvin A. Moses, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah A. Freedman-Cass

Although the panel members agreed that this topic cannot and should not be ignored, they believe that data do not support earlier or more intensive screening at this time. Race is, however, included as a baseline evaluation factor for risk assessment that

Full access

Robert Pilarski

a broadening of the range of patients who are offered testing, and the types of genes for which they are tested. For example, current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast

Full access

Daniel L. Hertz and Vaibhav Sahai

to the approximately 7% prevalence of carrying a potentially actionable DPYD allele. NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic recommend consideration of multigene panel testing for certain patients

Full access

Hyung L. Kim, Marvin R. Puymon, Maochun Qin, Khurshid Guru, and James L. Mohler

. Cooperberg MR Pasta DJ Elkin EP . The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy . J Urol 2005 ; 173 : 1938

Full access

Myeloid Leukemia Bladder Cancer Breast Cancer Genetic/Familial High-Risk Assessment: Breast and Ovarian Genetic/Familial High-Risk Assessment: Colorectal Hodgkin Lymphoma Lung Cancer Screening Neuroendocrine Tumors Pancreatic Adenocarcinoma

Full access

Harold J. Burstein

criteria for genetics evaluation and BRCA1/2 testing, as articulated by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancer. In choosing bilateral preventive mastectomy

Full access

Sean Dineen, Patrick M. Lynch, Miguel A. Rodriguez-Bigas, Sarah Bannon, Melissa Taggart, Colleen Reeves, Cathy Modaro, Michael Overman, George J. Chang, John M. Skibber, and Y. Nancy You

-high tumors or who had loss of expression of any of the MMR genes on IHC; (2) the number of those with “suggestive” tumor studies who received genetic counseling and risk assessment; and (3) the number of patients who completed the germline mutation testing

Full access

Robert W. Carlson

and supportive care topics. For example, this special edition includes a presentation on “Genetic Counseling in Patients with Familial Risk for Colorectal Cancer,” a topic that was translated into new NCCN Guidelines for Genetic/Familial High-Risk

Full access

Teresita Muñoz-Antonia

2005 ; 29 : 76 – 86 . 5. Vogel KJ Atchley DP Erlichman J . BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model . J Clin Oncol 2007 ; 25 : 4635 – 4641 . 6

Full access

Robert W. Carlson

/Familial High-Risk Assessment, which have begun to incorporate data to guide screening based on age-specific risks of genes included on multigene panels. Stephanie Andrews, MS, ANP-BC, of Moffitt Cancer Center, discussed the management of adverse events for